UY29882A1 - Antagonistas del receptor 3 de la histamina - Google Patents
Antagonistas del receptor 3 de la histaminaInfo
- Publication number
- UY29882A1 UY29882A1 UY29882A UY29882A UY29882A1 UY 29882 A1 UY29882 A1 UY 29882A1 UY 29882 A UY29882 A UY 29882A UY 29882 A UY29882 A UY 29882A UY 29882 A1 UY29882 A1 UY 29882A1
- Authority
- UY
- Uruguay
- Prior art keywords
- disease
- diseases
- compound
- formula
- gastrointestinal tract
- Prior art date
Links
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 1
- 229960001340 histamine Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 102000000543 Histamine Receptors Human genes 0.000 abstract 1
- 108010002059 Histamine Receptors Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000012886 Vertigo Diseases 0.000 abstract 1
- 230000009858 acid secretion Effects 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 208000027744 congestion Diseases 0.000 abstract 1
- 208000002173 dizziness Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000036543 hypotension Effects 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 231100000889 vertigo Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73099605P | 2005-10-27 | 2005-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY29882A1 true UY29882A1 (es) | 2007-05-31 |
Family
ID=37776539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY29882A UY29882A1 (es) | 2005-10-27 | 2006-10-25 | Antagonistas del receptor 3 de la histamina |
Country Status (39)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| BRPI0806473A2 (pt) * | 2007-01-22 | 2011-09-27 | Pfizer Prod Inc | sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo |
| EP2123644B1 (en) | 2007-03-07 | 2014-12-17 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| PL2195293T3 (pl) | 2007-08-22 | 2014-03-31 | Astrazeneca Ab | Pochodne cyklopropyloamidu |
| CA2708043C (en) * | 2007-12-07 | 2012-11-13 | Pfizer Inc. | Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-fluoro-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide |
| CN102015636B (zh) * | 2008-05-08 | 2014-08-13 | 埃沃特克股份有限公司 | 作为组胺h3受体拮抗剂的氮杂环丁烷类和环丁烷类化合物 |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| WO2011102795A1 (en) | 2010-02-18 | 2011-08-25 | Astrazeneca Ab | New crystalline form of a cyclopropyl benzamide derivative |
| WO2012131539A1 (en) | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
| JP6043355B2 (ja) | 2011-08-31 | 2016-12-14 | ファイザー・インク | ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| CA2872154C (en) | 2012-05-04 | 2016-08-23 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2 |
| EP2867236B1 (en) | 2012-06-29 | 2017-06-14 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| US9260455B2 (en) | 2012-09-20 | 2016-02-16 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| HK1215170A1 (zh) | 2012-11-14 | 2016-08-19 | The Johns Hopkins University | 治療精神分裂症的方法和組合物 |
| CA2893256A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| US9403846B2 (en) | 2012-12-19 | 2016-08-02 | Pfizer Inc. | Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| EP2956458B1 (en) | 2013-02-13 | 2017-08-09 | Pfizer Inc | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| EA201591360A1 (ru) | 2013-02-19 | 2016-03-31 | Пфайзер Инк. | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств |
| JP6425717B2 (ja) | 2013-10-04 | 2018-11-21 | ファイザー・インク | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| EA031419B1 (ru) | 2014-04-01 | 2018-12-28 | Пфайзер Инк. | ХРОМЕН И 1,1a,2,7b-ТЕТРАГИДРОЦИКЛОПРОПА[c]ХРОМЕН ПИРИДОПИРАЗИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРА ГАММА-СЕКРЕТАЗЫ |
| PE20170327A1 (es) | 2014-04-10 | 2017-04-21 | Pfizer | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| CU20170007A7 (es) | 2014-08-06 | 2017-06-05 | Pfizer | Compuestos de imidazopiridazina |
| MX368391B (es) | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
| UA125334C2 (uk) | 2015-06-17 | 2022-02-23 | Пфайзер Інк. | Трициклічні сполуки та їх застосування як інгібіторів фосфодіестерази |
| CN108137586B (zh) | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 |
| JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド |
| EP3353182A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
| HUE048658T2 (hu) | 2016-02-23 | 2020-07-28 | Pfizer | 6,7-dihidro-5H-pirazolo[5,1-b][1,3]oxazin-2-karboxamid vegyületek |
| DK3478679T3 (da) | 2016-07-01 | 2021-06-21 | Pfizer | 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme |
| SG10202110112TA (en) | 2017-03-10 | 2021-10-28 | Pfizer | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors |
| US11161844B2 (en) | 2017-03-10 | 2021-11-02 | Pfizer Inc. | Cyclic substituted imidazo[4,5-c]quinoline derivatives |
| CA3066077A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
| SG11201913014YA (en) | 2017-06-22 | 2020-01-30 | Pfizer | Dihydro-pyrrolo-pyridine derivatives |
| WO2019036725A2 (en) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | PEPTIDE INHIBITORS OF TAU AGGREGATION |
| CN112154145B (zh) | 2018-03-23 | 2023-10-17 | 辉瑞大药厂 | 哌嗪氮杂螺衍生物 |
| WO2022182658A1 (en) | 2021-02-23 | 2022-09-01 | Hoth Therapeutics, Inc. | Use of aprepitant for treating alzheimer's disease |
| CN116514645A (zh) * | 2023-04-08 | 2023-08-01 | 绍兴上虞华伦化工有限公司 | 二氟-4溴苯甲醛及其制备工艺 |
| WO2025145091A1 (en) | 2023-12-29 | 2025-07-03 | Pfizer Inc. | Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6559140B2 (en) | 2000-03-09 | 2003-05-06 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
| AU2002254114A1 (en) | 2001-03-23 | 2002-10-08 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| US7671047B2 (en) | 2002-06-19 | 2010-03-02 | Sanofi-Aventis Deutschland Gmbh | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| JP2004131497A (ja) * | 2002-09-18 | 2004-04-30 | Satoshi Shuto | シスシクロプロパン誘導体 |
| PL1651615T3 (pl) * | 2003-07-29 | 2010-08-31 | High Point Pharmaceuticals Llc | Pirydazynylo-piperazyny oraz ich zastosowanie jako ligandów receptora histaminowego H3 |
| EP1669350B1 (en) * | 2003-09-22 | 2012-02-29 | Msd K.K. | Piperidine derivatives |
| JP2007519707A (ja) | 2004-02-02 | 2007-07-19 | ファイザー・プロダクツ・インク | ヒスタミン−３受容体モジュレーター |
| SI1735278T1 (sl) * | 2004-04-01 | 2010-05-31 | Lilly Co Eli | Agenti histamin h receptorja priprava in terapevtska uporaba |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| ATE488496T1 (de) | 2005-06-22 | 2010-12-15 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| US8158673B2 (en) * | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| BRPI0806473A2 (pt) * | 2007-01-22 | 2011-09-27 | Pfizer Prod Inc | sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo |
-
2006
- 2006-10-13 US US11/549,175 patent/US8158673B2/en not_active Expired - Fee Related
- 2006-10-16 AP AP2008004401A patent/AP2403A/xx active
- 2006-10-16 JP JP2008537213A patent/JP4319245B2/ja not_active Expired - Fee Related
- 2006-10-16 CA CA2621323A patent/CA2621323C/en not_active Expired - Fee Related
- 2006-10-16 PT PT68091149T patent/PT1951660E/pt unknown
- 2006-10-16 RS RS20140034A patent/RS53153B/sr unknown
- 2006-10-16 EP EP06809114.9A patent/EP1951660B1/en active Active
- 2006-10-16 NZ NZ566488A patent/NZ566488A/en not_active IP Right Cessation
- 2006-10-16 PL PL06809114T patent/PL1951660T3/pl unknown
- 2006-10-16 RS RSP-2008/0173A patent/RS20080173A/sr unknown
- 2006-10-16 BR BRPI0617797-2A patent/BRPI0617797A2/pt not_active IP Right Cessation
- 2006-10-16 CN CN2006800399763A patent/CN101296898B/zh not_active Expired - Fee Related
- 2006-10-16 ES ES06809114.9T patent/ES2444370T3/es active Active
- 2006-10-16 WO PCT/IB2006/002977 patent/WO2007049123A1/en not_active Ceased
- 2006-10-16 AU AU2006307645A patent/AU2006307645B2/en not_active Ceased
- 2006-10-16 SI SI200631724T patent/SI1951660T1/sl unknown
- 2006-10-16 UA UAA200802656A patent/UA88719C2/ru unknown
- 2006-10-16 GE GEAP200610660A patent/GEP20104937B/en unknown
- 2006-10-16 HR HRP20140061TT patent/HRP20140061T1/hr unknown
- 2006-10-16 EA EA200800946A patent/EA013602B1/ru not_active IP Right Cessation
- 2006-10-16 DK DK06809114.9T patent/DK1951660T3/da active
- 2006-10-16 KR KR1020087009991A patent/KR101025358B1/ko not_active Expired - Fee Related
- 2006-10-20 NL NL1032713A patent/NL1032713C2/nl not_active IP Right Cessation
- 2006-10-24 PE PE2006001288A patent/PE20070720A1/es not_active Application Discontinuation
- 2006-10-25 GT GT200600471A patent/GT200600471A/es unknown
- 2006-10-25 UY UY29882A patent/UY29882A1/es not_active Application Discontinuation
- 2006-10-25 AR ARP060104658A patent/AR056879A1/es active IP Right Grant
- 2006-10-26 DO DO2006000239A patent/DOP2006000239A/es unknown
- 2006-10-26 TW TW095139560A patent/TWI318206B/zh not_active IP Right Cessation
- 2006-10-26 HN HN2006036385A patent/HN2006036385A/es unknown
-
2008
- 2008-02-28 IL IL189866A patent/IL189866A/en not_active IP Right Cessation
- 2008-04-02 TN TNP2008000150A patent/TNSN08150A1/fr unknown
- 2008-04-09 ZA ZA200803130A patent/ZA200803130B/xx unknown
- 2008-04-15 EC EC2008008373A patent/ECSP088373A/es unknown
- 2008-04-23 CU CU20080069A patent/CU23806B7/es not_active IP Right Cessation
- 2008-04-23 CR CR9910A patent/CR9910A/es not_active Application Discontinuation
- 2008-04-24 MY MYPI20081265A patent/MY145001A/en unknown
- 2008-04-25 MA MA30879A patent/MA29888B1/fr unknown
- 2008-04-28 NI NI200800132A patent/NI200800132A/es unknown
- 2008-05-16 NO NO20082264A patent/NO20082264L/no not_active Application Discontinuation
-
2009
- 2009-03-10 JP JP2009055839A patent/JP5064427B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-09 US US13/415,944 patent/US8389743B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY29882A1 (es) | Antagonistas del receptor 3 de la histamina | |
| ATE488496T1 (de) | Histamin-3-rezeptorantagonisten | |
| WO2007063385A3 (en) | Spirocyclic amine histamine-3 receptor antagonists | |
| BRPI0507374A (pt) | moduladores do receptor de histamina-3 | |
| WO2007105053A3 (en) | Tetralines antagonists of the h-3 receptor | |
| WO2007088450A3 (en) | Chromane antagonist of the h-3 receptor | |
| WO2007138431A3 (en) | Azabicyclic ether histamine-3 antagonists | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| BRPI0513486A (pt) | derivados de cicloamino 1,3 substituìdo e seu emprego como antagonistas de receptor de histamina-3 | |
| AR064963A1 (es) | Sal de tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma | |
| DOP2012000167A (es) | Moduladores alostericos positivos de receptores m1 de la quinolina amida | |
| EA201000609A1 (ru) | Замещенные пиперидинодигидротиенопиримидины | |
| EA201070535A1 (ru) | Новые агонисты глюкокортикоидных рецепторов | |
| CY1116452T1 (el) | Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης | |
| EA201590406A1 (ru) | Мочевинные и амидные производные аминоалкилпиперазинов и их применение | |
| BRPI0510501A (pt) | antagonistas do receptor 3 de histamina | |
| BRPI0513444A (pt) | antagonistas do receptor da histamina 3 | |
| SV2009002917A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos | |
| MX2007003587A (es) | Antagonistas de los receptores de histamina-3. | |
| AR069611A1 (es) | Sal tosilato de un compuesto terapeutico y composiciones farmaceuticas de la misma | |
| BRPI0512567A (pt) | compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas | |
| WO2006024955A8 (en) | Azabicyclic amine histamine-3 receptor antagonists | |
| AR067675A1 (es) | 2-azetidinametanoaminas y 2-pirrolidinametanoaminas como ligandos de taar, un metodo para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento de trastornos del snc. | |
| CY1114789T1 (el) | Ανταγωνιστες υποδοχεα ισταμινης-3 | |
| ATE393148T1 (de) | Neue benzimidazolderivative und ihre pharmazeutische zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20160920 |